Tertomotide
DRACPC ID DRACPC0010
Active Ingredients Tertomotide
Description A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.
Synonyms GV 1001; GV-1001; GV1001; PrimoVax; Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment); Tertomotide
Type Biotech
Disease Non-small Cell Lung Cancer, Leukemia, Pancreatic Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C85H146N26O21
Molecular Weight 1868.2
Active Sequence EARPALLTSRLRFIPK
Sequence Length 16
Modification None
IUPAC Name (2S)-6-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
InChI InChI=1S/C85H146N26O21/c1-12-47(8)65(81(130)111-38-22-30-63(111)78(127)102-56(82(131)132)25-16-17-33-86)108-75(124)60(42-51-23-14-13-15-24-51)106-71(120)53(26-18-34-94-83(88)89)99-72(121)58(40-45(4)5)104-70(119)54(27-19-35-95-84(90)91)100-76(125)61(43-112)107-79(128)66(50(11)113)109-74(123)59(41-46(6)7)105-73(122)57(39-44(2)3)103-68(117)49(10)98-77(126)62-29-21-37-110(62)80(129)55(28-20-36-96-85(92)93)101-67(116)48(9)97-69(118)52(87)31-32-64(114)115/h13-15,23-24,44-50,52-63,65-66,112-113H,12,16-22,25-43,86-87H2,1-11H3,(H,97,118)(H,98,126)(H,99,121)(H,100,125)(H,101,116)(H,102,127)(H,103,117)(H,104,119)(H,105,122)(H,106,120)(H,107,128)(H,108,124)(H,109,123)(H,114,115)(H,131,132)(H4,88,89,94)(H4,90,91,95)(H4,92,93,96)
InChI_Key WZJRQXZSYQYFJV-UHFFFAOYSA-N
SMILES CCC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C1CCCN1C(C(NC(C(NC(C(N)CCC(O)=O)=O)C)=O)CCC/N=C(N)/N)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)C(O)C)=O)CO)=O)CCC/N=C(N)\N)=O)CC(C)C)=O)CCC/N=C(N)\N)=O)CC2=CC=CC=C2)=O)C(N3CCCC3C(NC(C(O)=O)CCCCN)=O)=O)C
External Codes
PubChem CID 56843375
DrugBank Accession Number DB12747
NCI Thesaurus Code C62756
UNII 55R7RG342O GSRS
CAS 915019-08-8
Drug approval
Drug indication
Investigated for use/treatment in Non-small Cell Lung Cancer, Leukemia, Pancreatic Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02854072 | A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients | Pancreatic Cancer | Phase 3 | Treatment |
| NCT00444782 | "Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma. | Carcinoma, Hepatocellular | Phase 2 | Treatment |
| NCT01247623 | Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma | Malignant Melanoma | Phase 1/2 | Treatment |
| NCT04032067 | A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) | Benign Prostatic Hyperplasia (BPH) | Phase 3 | Treatment |
| NCT03184467 | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients | Alzheimer Disease | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
